FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974583668> ?p ?o ?g. }

• W1974583668 endingPage "683" @default.
• W1974583668 startingPage "683" @default.
• W1974583668 abstract "Emerging treatments in type 2 diabetes: focus on canagliflozin Marek Rosiak,1,2 Susanna Grzeszczak,2 Dariusz A Kosior,2,3 Marek Postuła1,2 1Department of Cardiology and Hypertension, Central Clinical Hospital, the Ministry of the Interior, Warsaw, Poland; 2Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland; 3Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland Abstract: Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder, which affects more than 300 million people globally. The common effect of uncontrolled diabetes is the state of hyperglycemia, which results from beta-cell dysfunction as well as insulin resistance, which is accompanied with microvascular and macrovascular complications. As hyperglycemia defines diabetes, glycemic control is fundamental to the management of diabetes. Sodium glucose co-transporter 2 inhibitors (SGLT2) are a new group of oral antidiabetic medications that act by blocking the reabsorption of glucose, causing it to be excreted in the urine. Canagliflozin was the first SGLT2 inhibitor to be approved in the US by the Food and Drug Administration for the treatment and control of T2DM and on September 19, 2013, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Invokana®. Canagliflozin is a SGLT2 inhibitor, which acts upon the proximal tubules of the kidneys and reduces the renal threshold for glucose. It is highly selective, binding 250 times more potently to SGLT2 than sodium glucose co-transporter 1 inhibitor. This action allows a higher amount of glucose to be excreted within the urine, causing the patient's plasma glucose level to be decreased and indirectly causing weight loss. Among the most common adverse events are hypoglycemia, headache, nausea, female genital and urinary tract infections, nasopharyngitis, and transient postural dizziness. Given its high efficacy in reducing hyperglycemia and good safety profile as either monotherapy or an add-on treatment to metformin, sulfonylureas, or insulin, canagliflozin seems to be a promising antihyperglycemic drug. Nevertheless, further large-scale and long-term studies should be conducted to evaluate the impact of canagliflozin on cardiovascular risk in T2DM patients. Keywords: hyperglycemia, SGLT2 inhibitor, hypertension, dapagliflozin, insulin resistance, obesity, blood pressure, weight loss" @default.
• W1974583668 created "2016-06-24" @default.
• W1974583668 creator A5018345279 @default.
• W1974583668 creator A5026059424 @default.
• W1974583668 creator A5053832393 @default.
• W1974583668 creator A5068675763 @default.
• W1974583668 date "2014-08-01" @default.
• W1974583668 modified "2023-10-03" @default.
• W1974583668 title "Emerging treatments in type 2 diabetes: focus on canagliflozin" @default.
• W1974583668 cites W1968145432 @default.
• W1974583668 cites W1997018189 @default.
• W1974583668 cites W1999892123 @default.
• W1974583668 cites W2015696027 @default.
• W1974583668 cites W2036504033 @default.
• W1974583668 cites W2038961968 @default.
• W1974583668 cites W2068171948 @default.
• W1974583668 cites W2077038286 @default.
• W1974583668 cites W2084511068 @default.
• W1974583668 cites W2090563376 @default.
• W1974583668 cites W2130189158 @default.
• W1974583668 cites W2130570549 @default.
• W1974583668 cites W2134693989 @default.
• W1974583668 cites W2149185387 @default.
• W1974583668 cites W2167984652 @default.
• W1974583668 cites W2514433048 @default.
• W1974583668 cites W32021996 @default.
• W1974583668 doi "https://doi.org/10.2147/tcrm.s39145" @default.
• W1974583668 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4149387" @default.
• W1974583668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25187722" @default.
• W1974583668 hasPublicationYear "2014" @default.
• W1974583668 type Work @default.
• W1974583668 sameAs 1974583668 @default.
• W1974583668 citedByCount "5" @default.
• W1974583668 countsByYear W19745836682017 @default.
• W1974583668 countsByYear W19745836682018 @default.
• W1974583668 countsByYear W19745836682019 @default.
• W1974583668 countsByYear W19745836682022 @default.
• W1974583668 crossrefType "journal-article" @default.
• W1974583668 hasAuthorship W1974583668A5018345279 @default.
• W1974583668 hasAuthorship W1974583668A5026059424 @default.
• W1974583668 hasAuthorship W1974583668A5053832393 @default.
• W1974583668 hasAuthorship W1974583668A5068675763 @default.
• W1974583668 hasBestOaLocation W19745836681 @default.
• W1974583668 hasConcept C126322002 @default.
• W1974583668 hasConcept C134018914 @default.
• W1974583668 hasConcept C2777180221 @default.
• W1974583668 hasConcept C2777451236 @default.
• W1974583668 hasConcept C2780473172 @default.
• W1974583668 hasConcept C2910068830 @default.
• W1974583668 hasConcept C555293320 @default.
• W1974583668 hasConcept C71924100 @default.
• W1974583668 hasConcept C98274493 @default.
• W1974583668 hasConceptScore W1974583668C126322002 @default.
• W1974583668 hasConceptScore W1974583668C134018914 @default.
• W1974583668 hasConceptScore W1974583668C2777180221 @default.
• W1974583668 hasConceptScore W1974583668C2777451236 @default.
• W1974583668 hasConceptScore W1974583668C2780473172 @default.
• W1974583668 hasConceptScore W1974583668C2910068830 @default.
• W1974583668 hasConceptScore W1974583668C555293320 @default.
• W1974583668 hasConceptScore W1974583668C71924100 @default.
• W1974583668 hasConceptScore W1974583668C98274493 @default.
• W1974583668 hasLocation W19745836681 @default.
• W1974583668 hasLocation W19745836682 @default.
• W1974583668 hasLocation W19745836683 @default.
• W1974583668 hasLocation W19745836684 @default.
• W1974583668 hasOpenAccess W1974583668 @default.
• W1974583668 hasPrimaryLocation W19745836681 @default.
• W1974583668 hasRelatedWork W2019509271 @default.
• W1974583668 hasRelatedWork W2119121134 @default.
• W1974583668 hasRelatedWork W2125102063 @default.
• W1974583668 hasRelatedWork W2127396703 @default.
• W1974583668 hasRelatedWork W2153591790 @default.
• W1974583668 hasRelatedWork W2804314221 @default.
• W1974583668 hasRelatedWork W2903785509 @default.
• W1974583668 hasRelatedWork W3107933435 @default.
• W1974583668 hasRelatedWork W4237246611 @default.
• W1974583668 hasRelatedWork W4247190821 @default.
• W1974583668 isParatext "false" @default.
• W1974583668 isRetracted "false" @default.
• W1974583668 magId "1974583668" @default.
• W1974583668 workType "article" @default.